GYRE THERAPEUTICS, INC. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2019 to Q1 2022

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Gyre Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2019 to Q1 2022.
  • Gyre Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending March 31, 2022 was $564K, a 43.9% decline year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2022 $564K -$442K -43.9% Mar 31, 2022 10-Q 2022-05-09
Q4 2021 $1.82M -$1.5M -45.1% Dec 31, 2021 10-Q 2022-05-09
Q3 2021 $1.11M -$441K -28.4% Sep 30, 2021 10-Q 2021-11-12
Q2 2021 $1.97M -$17K -0.86% Jun 30, 2021 10-Q 2021-08-05
Q1 2021 $1.01M -$360K -26.4% Mar 31, 2021 10-Q 2021-05-06
Q4 2020 $3.31M -$11.7M -77.9% Dec 31, 2020 10-K 2022-03-31
Q3 2020 $1.56M Sep 30, 2020 10-Q 2020-11-05
Q2 2020 $1.99M Jun 30, 2020 10-Q 2020-08-06
Q1 2020 $1.37M Mar 31, 2020 10-Q 2020-05-11
Q4 2019 $15M Dec 31, 2019 10-K 2021-03-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.